Nascent Biotech, Inc. (OTCMKTS:NBIO) Short Interest Up 143.1% in June

Nascent Biotech, Inc. (OTCMKTS:NBIOGet Rating) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 49,600 shares, a growth of 143.1% from the May 31st total of 20,400 shares. Based on an average daily trading volume, of 1,226,800 shares, the short-interest ratio is presently 0.0 days.

Shares of OTCMKTS:NBIO traded up $0.01 during trading on Friday, hitting $0.30. 70,054 shares of the company were exchanged, compared to its average volume of 247,890. The business’s 50 day moving average is $0.16 and its 200-day moving average is $0.10. Nascent Biotech has a 1-year low of $0.04 and a 1-year high of $0.32.

Nascent Biotech Company Profile (Get Rating)

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.

Read More

Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.